News & Updates
Filter by Specialty:
High-dose radiotherapy boosts biochemical control in Gleason 9–10 prostate cancer
In patients with clinically localized Gleason 9–10 prostate cancer, dose-escalated radiotherapy confers better biochemical disease-free survival and prostate cancer-specific mortality than conventional doses, a recent study has found.
High-dose radiotherapy boosts biochemical control in Gleason 9–10 prostate cancer
15 Jan 2022
What is the ideal number of NACT cycles for muscle invasive bladder cancer?
Four cycles of neoadjuvant chemotherapy (NACT) results in better pathological response and survival than three NACT cycles in patients with muscle invasive bladder cancer, reveals a recent study.
What is the ideal number of NACT cycles for muscle invasive bladder cancer?
06 Jan 2022
Robotic-assisted radical cystectomy for bladder cancer: Intracorporeal urinary diversion of benefit
Intracorporeal urinary diversion (ICUD) is associated with similar postoperative complication rates, reduced blood loss and shorter hospitalization vs extracorporeal urinary diversion (ECUD) in patients undergoing robotic-assisted radical cystectomy (RARC) for localized bladder cancer, data from the Asian RARC Consortium registry have shown.
Robotic-assisted radical cystectomy for bladder cancer: Intracorporeal urinary diversion of benefit
06 Jan 2022
Interval between biopsy and RARP does not impact biochemical recurrence in prostate cancer
A prolonged gap between biopsy and robot-assisted radical prostatectomy (RARP) does not significantly influence the likelihood of biochemical recurrence (BCR) in prostate cancer patients, even in those who are considered high-risk, a recent Japan study has found.
